Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 5/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | LAP3 | P28838 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.31 |
| ▸ | ADH7 | P40394 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 3/20 | 0.30 |
| ▸ | MMP3 | P08254 | 3/20 | 0.30 |
| ▸ | MMP1 | P03956 | 2/20 | 0.30 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
| ▸ | MMP7 | P09237 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27818797 | 0.78 | OPRM1 (0.39) | FDPSOPRM1LMNAADH1BADH1C | |
| SCHEMBL14198303 | 0.78 | LMNA (0.48) | FDPSOPRM1LMNAADH1BADH1C | |
| SCHEMBL26511932 | 0.78 | OPRM1 (0.39) | FDPSOPRM1LMNAADH1BADH1C | |
| SCHEMBL20016450 | 0.78 | ALDH1A1 (0.39) | FDPSCA1LMNACA2 | |
| SCHEMBL20016391 | 0.78 | ALDH1A1 (0.39) | FDPSCA1LMNACA2 | |
| SCHEMBL23686853 | 0.76 | LMNA (0.39) | FDPSOPRM1LMNAADH1BADH1C | |
| SCHEMBL10491044 | 0.76 | LMNA (0.39) | FDPSOPRM1LMNAADH1BADH1C | |
| SCHEMBL9624771 | 0.76 | EPHX1 (0.44) | FDPSOPRM1LMNAADH1BADH1C | |
| SCHEMBL3840048 | 0.76 | LMNA (0.41) | OPRM1LMNAADH1BADH1CADH1A | |
| SCHEMBL28268989 | 0.76 | LMNA (0.39) | FDPSOPRM1LMNAADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | CD274, PDCD1, PDCD1LG2 | FDPS 3556/4885OPRM1 1602/4885CA1 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.